The NCI Experimental Therapeutics (NExT) pipeline is designed to assist translation to the clinic of novel therapeutic interventions, either synthetic, natural product, or biologic, arising from academic, private, or government entities. NExT is not a grant mechanism. Approved proposals gain access to drug discovery and development resources through the NExT Program. A panel of experts will review the applications based on criteria including scientific merit, feasibility, alignment with NCI mission, novelty, and clinical need. The NExT Program will send notification letters informing applicants of the review of their proposals four to six months after their submission deadline. For more information, see Instructions to applicants.
Please Note: Applicants who are requesting early discovery resources should be aware that such resourcing is done via the NCI's Chemical Biology Consortium (CBC). Applicants whose projects are approved will be invited to join the CBC and are expected to become signatories to the CBC Participants Agreement. If you are submitting an early discovery NExT Program application, you are expected to have read and understood the referenced agreement and to have contacted your institution's or company's Technology Transfer Office to make certain that your organization is willing to accept the terms of this agreement.
Applicants may also apply for access to the CBC compound library for their screening activities. These applications will also undergo peer-review.
NExT proposals are accepted following the schedule below:
|Cycle Open for Submission||Submission Deadline|
|January 15, 2013||February 15, 2013|
|May 15, 2013||June 15, 2013|
|September 15, 2013||October 15, 2013|
|January 15, 2014||February 15, 2014|
|May 15, 2014||June 15, 2014|
Applications are due by 5:00 PM Eastern Time on the deadline dates. Applications will not be accepted after the deadline. Applicants are advised to finalize submission of their proposals prior to the deadline date.
All proposals must be submitted online via the proposalCENTRAL site. Please note that the Principal Investigator (the Applicant) is responsible for final submission.